Weekly low-dose methotrexate for reduction of Global Initiative for Asthma Step 5 treatment in severe refractory asthma: study protocol for a randomized controlled trial

Riccardo Polosa, Salvatore Bellinvia, Massimo Caruso, Rosalia Emma, Angela Alamo, Marek Leszek Kowalski, Christian Domingo, Riccardo Polosa, Salvatore Bellinvia, Massimo Caruso, Rosalia Emma, Angela Alamo, Marek Leszek Kowalski, Christian Domingo

Abstract

Background: Patients with chronic severe asthma (CSA) have a crippling disease and current available treatments are not satisfactory. Thus, management of CSA remains a major unmet need. Although the evidence from existing randomized controlled trials fails to support a definite role for immunomodulatory drugs in these patients due to major methodologic drawbacks, findings with low-dose methotrexate (MTX) are encouraging. However, larger and well-designed clinical trials are required to establish the beneficial role of MTX in CSA, and for the detection of the key characteristics of those who are going to respond to this drug.

Methods/design: Patients will be recruited from the accessible asthmatic patients lists of tertiary referral centers. All patients will meet the stringent diagnostic criteria for CSA, including the requirement for the regular use of Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention Step 5 medications (oral prednisone and/or omalizumab). The experimental design of the proposed study will take the form of a double-blind parallel-randomized placebo-controlled trial consisting of a total of eight visits, including run-in and run-out periods. Patients will be randomly allocated to receive either MTX or a matched placebo once a week as an add-on therapy to their existing medication after run-in. Physiological, laboratory and clinical assessments will be measured regularly throughout the study and compared with baseline assessments.

Discussion: We expect that MTX will reduce Step 5 medications dosage in patients with CSA without compromising the overall disease control. Improvement in several indicators of asthma severity and control will be also investigated.

Trial registration: ClinicalTrials.gov Identifier: NCT02124226 (assigned 25 April 2014).

Figures

Figure 1
Figure 1
A schematic diagram of the study design. MTX: Methotrexate. PROs: Patient Reported Outcomes. US: Ultrasound. MTXPG: Methotrexate Polyglutamate. AEs: Adverse Events.

References

    1. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program Global Initiative for Asthma (GINA) program: the global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469–478. doi: 10.1111/j.1398-9995.2004.00526.x.
    1. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC) Eur Respir J. 1998;12:315–335. doi: 10.1183/09031936.98.12020315.
    1. Braman SS. Asthma in the elderly. Clin Geriatr Med. 2003;19:57–75. doi: 10.1016/S0749-0690(02)00052-6.
    1. Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM. Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res. 2011;12:114. doi: 10.1186/1465-9921-12-114.
    1. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8:218–230. doi: 10.1038/nri2262.
    1. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF, Jr, Wardlaw AJ, Wenzel SE, Greenberger PA. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127:355–360. doi: 10.1016/j.jaci.2010.11.037.
    1. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;368:780–793. doi: 10.1016/S0140-6736(06)69288-X.
    1. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, Calhoun WJ, Castro M, Chung KF, Clark MP, Dweik RA, Fitzpatrick AM, Gaston B, Hew M, Hussain I, Jarjour NN, Israel E, Levy BD, Murphy JR, Peters SP, Teague WG, Meyers DA, Busse WW, Wenzel SE, National Heart, Lung, Blood Institute’s Severe Asthma Research Program Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119:405–413. doi: 10.1016/j.jaci.2006.11.639.
    1. British Thoracic Society Scottish Intercollegiate Guidelines network BTS/SIGN British Guideline on Management of asthma. Thorax. 2008;63(Suppl 4):iv1–iv121. doi: 10.1136/thx.2008.097741.
    1. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity, a 1 year prospective study. Eur Respir J. 2002;19:61–67. doi: 10.1183/09031936.02.00232001.
    1. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, Eichler H-G, Zhang Q, Yin DD. Asthma severity and medical resource utilization. Eur Respir J. 2004;23:723–729. doi: 10.1183/09031936.04.00004904.
    1. Akinbami LJ, Schoendorf KC. Trends in childhood asthma: prevalence, health care utilization, and mortality. Pediatrics. 2002;110:315–322. doi: 10.1542/peds.110.2.315.
    1. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J. 1998;12:1209–1218. doi: 10.1183/09031936.98.12051209.
    1. Gaga M, Zervas E, Grivas S, Castro M, Chanez P. Evaluation and management of severe asthma. Curr Med Chem. 2007;14:1049–1059. doi: 10.2174/092986707780362961.
    1. Polosa R. An overview of chronic severe asthma. Intern Med J. 2008;38:190–198. doi: 10.1111/j.1445-5994.2007.01547.x.
    1. Colice GL, Stampone P, Leung DY, Szefler SJ. Oral corticosteroids in poorly controlled asthma. J Allergy Clin Immunol. 2005;115:200–201. doi: 10.1016/j.jaci.2004.07.065.
    1. Domingo C, Moreno A, Jose Amengual M, Monton C, Suarez D, Pomares X. Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients. Curr Med Res Opin. 2011;27:45–53. doi: 10.1185/03007995.2010.536208.
    1. GINA: The global strategy for asthma management and prevention (updated 2012) []
    1. Polosa R, Casale T. Monoclonal antibodies for chronic refractory asthma and pipeline developments. Drug Discov Today. 2012;17:591–599. doi: 10.1016/j.drudis.2012.01.012.
    1. Caruso M, Crisafulli E, Lizzio R, Polosa R. Biologic therapy for atopic asthma and beyond. Curr Opin Allergy Clin Immunol. 2013;13:677–685. doi: 10.1097/ACI.0000000000000012.
    1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328–346. doi: 10.1002/art.10148.
    1. Polosa R, Morjaria J. Immunomodulatory and biologic therapies for severe refractory asthma. Respir Med. 2008;102:1499–1510. doi: 10.1016/j.rmed.2008.09.006.
    1. Mathew J, Aronow WS, Chandy D. Therapeutic options for severe asthma. Arch Med Sci. 2012;8:589–597. doi: 10.5114/aoms.2012.30280.
    1. Comet R, Domingo C, Larrosa M, Moron A, Rue M, Amengual MJ, Marìn A. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study. Respir Med. 2006;100:411–419. doi: 10.1016/j.rmed.2005.07.003.
    1. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316. doi: 10.1111/j.1398-9995.2004.00772.x.
    1. Bernstein DI, Dubb JW, Faiferman I, Wallin B, Participants of the Auranofin Multicenter Drug Trial A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol. 1996;98:317–324. doi: 10.1016/S0091-6749(96)70156-2.
    1. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax. 2008;63:584–591. doi: 10.1136/thx.2007.086314.
    1. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P, T03 Asthma Investigators A randomized, double-blind, placebo-controlled study of TNFalpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549–558. doi: 10.1164/rccm.200809-1512OC.
    1. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81–87. doi: 10.1016/0895-4356(94)90036-1.
    1. Juniper EF, Svensson K, Mork A-C, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553–558. doi: 10.1016/j.rmed.2004.10.008.
    1. Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olason I, Wetzel CE. Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study. N Engl J Med. 1988;318:603–607. doi: 10.1056/NEJM198803103181004.
    1. Shiner RJ, Nunn AJ, Chung KF, Geddes DM. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet. 1990;336:137–140. doi: 10.1016/0140-6736(90)91659-X.
    1. Domingo C, Moreno A, Amengual MJ, Comet R, Lujan M. Twelve years’ experience with methotrexate for GINA treatment step 5 asthma patients. Curr Med Res Opin. 2009;25:367–374. doi: 10.1185/03007990802643466.
    1. Mullarkey MF, Lammert JK, Blumenstein BA. Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med. 1990;112:577–581. doi: 10.7326/0003-4819-112-8-577.
    1. Shiner RJ, Katz I, Shulimzon T, Silkoff P, Benzaray S. Methotrexate in steroid-dependent asthma: long-term results. Allergy. 1994;49:565–568. doi: 10.1111/j.1398-9995.1994.tb01130.x.
    1. Corrigan CJ, Shiner R, Shakur BH, Ind PW. Methotrexate therapy in asthma increases T cell susceptibility to corticosteroid inhibition. Clin Exp Allergy. 2003;33:1090–1096. doi: 10.1046/j.1365-2222.2003.t01-1-01723.x.
    1. Domingo C, Moreno A, Mirapeix R. Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids. Intern Med J. 2011;41:525–536. doi: 10.1111/j.1445-5994.2011.02481.x.
    1. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH, Wagers SS, Sterk PJ, Compton CH, Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI) Thorax. 2011;66:910–917. doi: 10.1136/thx.2010.153643.
    1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373. doi: 10.1183/09031936.00202013.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit